Our Platform
A powerful new type of antibody therapeutic
that unlocks cell surface targets
By linking potent and selective small molecules to effector antibodies in a unique way, we can target cell surface proteins that are not addressable using other therapeutic modalities
- Using best-in-class small molecule binders, we can access deep binding pockets in receptors such as G protein-coupled receptors (GPCRs) and ion channels.
- We engineer the binders into bifunctional small molecules. One arm engages the extracellular target while the other arm utilizes our proprietary platform linker technology to connect with one of our proprietary antibodies.
- Our innovative linker technology allows us to create an entirely new class of drugs where bifunctional small molecules adopt the pharmacokinetic properties and functions of our antibodies.
- This unique ability to combine our bifunctional small molecules and antibodies allows us to develop new medicines that were previously impossible to create.
Unlock Targets
Access high value drug discovery targets that cannot be accessed using traditional therapeutic antibodies
Rapid Drug Development
Covalently attaching proprietary linkers to readily available clinical quality small molecules makes it possible for Solu to advance from concept to development candidate in about one year
Enhanced Specificity and Efficacy
The very low small molecule doses required in the Solu platform decrease safety risks, and the deep binding pockets for small molecules on drug targets enhance the efficacy of effector antibodies
CyTAC™
Cytotoxicity Targeting Chimera
Our proprietary CyTAC molecules link cell surface targets that mark pathogenic cells to proprietary platform antibodies that induce the killing of these cells
TicTAC™
Therapeutic Index Control Targeting Chimera
Our proprietary TicTAC molecules drive the tight association of potent and selective small molecule agonists or antagonists with an Fc-modified antibody, leading to the small molecule assuming the pharmacokinetic characteristics of the antibody. This can provide multiple advantages resulting in a superior profile for the therapeutic.
Pipeline
Our opportunity to target multiple areas of unmet need
Oncology
CyTAC Platform: Eliminate tumor cells
- Unlock novel selective tumor antigens
- Target single- or dual-tumor antigens with heterobivalent small molecule CyTACs
- Pair CyTACs with proprietary ADCC-enhanced, ADC, or bispecific platform antibodies.
- Enable potent and selective killing of hematologic and solid tumor cells
Immunology and Inflammation
CyTAC Platform: Eliminate pathogenic immune cells
- Unlock novel drug discovery targets and therapeutic approaches specific to a range of immunological cell types
- Potently deplete specific pathogenic immune cell subsets
- Eliminate cells known to drive immunological and inflammatory disease
Other Therapeutic Areas
TicTAC Platform: Enable long-acting antagonism and agonism
- Focus on high value cell surface targets which are not amenable to binding classic therapeutic antibodies
- Support development of potent, selective and long-acting antagonistic or agonistic small molecule therapeutics
- Broad therapeutic applicability to targets across a wide range of therapeutic areas
Oncology
STX-0712
STX-0301
Immunology & Inflammation
STX-0812
STX-0640
Pain
Na ion channel TicTACs
Collaborate With Us
Submit ideas or contact us for collaboration opportunities
Our proprietary platform and approach present multiple opportunities for collaboration or partnership around existing programs or the potential to use our platform to support development of new medicines.
About Solu
We are a Therapeutic Platform Company
Our History
An industrialized platform with transformational potential
Solu Therapeutics was established in May 2023 following the granting of an exclusive license to the CyTAC platform from GSK. Our lead CyTAC program is planned to enter the clinic in early 2025, with a number of exciting CyTAC and TicTAC programs advancing to development candidate status.
Our Mission
To develop a new generation of medicines that transform patient lives
Our Team
Leadership
Phil Vickers, PhD
Michael Boretti, PhD
Brandon Turunen, PhD
Kelly Honohan, JD
John McCabe, MBA
John Pribis, PhD
Craig Leach, PhD
Ron Swearingen, MS
Susan Ward, PhD
Board Members
Christoph Westphal, MD, PhD
Phil Vickers, PhD
Omar Khalil, MSE
John Hamer, PhD
Satoshi Konagai, MBA, MSc
Peter Barton Hutt, LL.B., LL.M.
Scientific Advisory Board
Kipp Weiskopf, MD, PhD
Kai Wucherpfennig, MD, PhD
Stephen Hodi, MD
Kenneth W. Hance, PhD, MPH
Gary Gordon, MD, PhD
Phillip Low, PhD
Investors
News
Careers
Working at Solu
Solu Therapeutics is a dynamic group of hard-working professionals dedicated to transforming the treatment of diseases by developing groundbreaking medicines. Our team-oriented culture values collaboration, creativity, and fun, fostering an environment where talented individuals can thrive. We're passionate about making a positive difference for people living with many serious and challenging diseases, and we welcome like-minded talents to join our mission.
Job Openings
There are no open positions at this time. To inquire about future opportunities, please reach out via email.
careers@solutherapeutics.com